Aptevo Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

APVO$1.08-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)

	For the Nine Months Ended September 30,
	2024	2023
Operating Activities
Net loss	$(17,818)	$(11,508)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,141	1,835
Depreciation and amortization	281	451
Non-cash interest expense and other	—	10
Changes in operating assets and liabilities:
Royalty receivable	—	2,500
Prepaid expenses and other current assets	(96)	299
Operating lease right-of-use asset	361	311
Accounts payable, accrued compensation and other liabilities	(1,341)	129
Long-term operating lease liability	(554)	(504)
Net cash used in operating activities	(18,026)	(6,477)
Investing Activities
Net cash from investing activities	—	—
Financing Activities
Payments of long-term debt, including fees	—	(3,467)
Value of equity awards withheld for tax liability	(1)	(8)
Proceeds from issuance of common stock and pre-funded warrants	8,879	6,427
Payments in lieu of fractional shares	(3)	—
Net cash provided by financing activities	8,875	2,952
Decrease in cash and cash equivalents	(9,151)	(3,525)
Cash and cash equivalents at beginning of period	16,904	22,635
Cash and cash equivalents at end of period	$7,753	$19,110
Supplemental Cash Flow Information
Warrant modification - incremental value	$472	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.